Carnyx Therapeutics reported that its oral preclinical candidate CNYX-005, derived from peptide biology associated with Epitalon, increased total sleep by roughly 1.5 to 2 hours in aged rats, with the gain concentrated in non-REM sleep measured by continuous EEG. The company frames the result as a shift in sleep architecture rather than simple sedation, relevant because deep NREM sleep declines with age and supports hormone secretion and tissue repair. No human data, dosing details, animal numbers, or trial timeline have been disclosed.
Key Points
- Aged rats gained 1.5–2 hours sleep, mostly non-REM
- EEG data suggest altered sleep architecture, not sedation
- Preclinical only; no dosing, sample size, or trial timeline
Longevity Analysis
Deep NREM sleep is the window in which growth hormone pulses, glymphatic clearance, and tissue repair concentrate, and its erosion with age is among the more measurable declines in nocturnal physiology. A compound that restores sleep depth rather than simply extending unconsciousness would address the architecture itself, which is the variable that matters for overnight recovery and metabolic regulation. Until human EEG data exist, the practical leverage remains in removing what fragments deep sleep — evening light, alcohol, late stimulants, thermal load — and tracking sleep staging objectively rather than by perceived rest.
Original published by Longevity.Technology, by Kyle Umipig.